MedTrace Logo

Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study

NCT04828434 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-03-25

No results posted yet for this study

Summary

Due to COVID-19, the routine treatment for dementia, Cognitive Stimulation Therapy (CST), is currently suspended in multiple countries. Access to treatment is, therefore, paramount. The investigators seek to bridge the current treatment gap with a virtual and individual form of CST, called Virtual Individual Cognitive Stimulation Therapy (V-iCST). This psychosocial intervention was adapted from the key principles of CST and developed within the Medical Research Council (MRC) framework for complex interventions. The investigators aim to evaluate the feasibility and acceptability of V-iCST in a Randomized Controlled Trial.

This is a feasibility randomized controlled trial (RCT) for Virtual Individual Cognitive Stimulation Therapy (V-iCST), an evidence-based teletherapy for people with mild to moderate dementia. This psychosocial intervention is adapted from a routine and established dementia treatment, Cognitive Stimulation Therapy, and developed within the Medical Research Council (MRC) framework for complex interventions.

Conditions

  • Dementia
  • Dementia, Vascular
  • Dementia, Mixed
  • Dementia With Lewy Bodies
  • Dementia Frontal
  • Dementia, Mild
  • Dementia Moderate
  • Dementia Alzheimers
  • Dementia of Alzheimer Type
  • Dementia, Multi-Infarct
  • Dementia Frontotemporal

Interventions

OTHER

Virtual Individual Cognitive Simulation Therapy

Virtual Individual Cognitive Stimulation Therapy (V-iCST) is an individual and virtual adaptation of Cognitive Stimulation Therapy (CST), a routine psychosocial treatment for people with mild to moderate dementia in the UK.

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Aimee Spector, PhD, DClinPsy · UCL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-04-01
Completion
2025-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828434 on ClinicalTrials.gov